Values First Advisors’s ADC Therapeutics ADCT Stock Holding History

Values First Advisors’s Portfolio ADCT Stock Details ADCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-13,019	Closed	-$25.4K	–	171
2023 Q1	$25.4K	Buy	13,019 +2,619	+25%	+$9.66K	0.02%	211
2022 Q4	$39.9K	Buy	+10,400	New	+$41.6K	0.03%	150

Other funds holding ADCT

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Values First Advisors's ADCT Position: Q2 2023 in Review

Values First Advisors sold out of ADC Therapeutics (ADCT) in Q2 2023, closing a stake of 13,019 shares — an estimated $25.4K sold.

Values First Advisors first reported a position in ADCT in Q4 2022 and held it in 2 quarters. The position peaked at $39.9K in Q4 2022. 56 funds tracked by Wall St. Rank hold ADCT as of Q2 2023.

Values First Advisors reported no remaining ADC Therapeutics position as of Q2 2023 after selling out during the quarter.
Values First Advisors sold 13,019 ADC Therapeutics shares in Q2 2023, an estimated $25.4K.
Values First Advisors first reported a position in ADC Therapeutics in Q4 2022 and held it in 2 quarters.
Values First Advisors's ADC Therapeutics position peaked at $39.9K in Q4 2022.
56 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2023.

Based on Values First Advisors's 13F filing for Q2 2023, filed 2 Aug 2023.